Your browser doesn't support javascript.
loading
Transcriptome profiling reveals that VNPP433-3ß, the lead next-generation galeterone analog inhibits prostate cancer stem cells by downregulating epithelial-mesenchymal transition and stem cell markers.
Thomas, Elizabeth; Thankan, Retheesh S; Purushottamachar, Puranik; Huang, Weiliang; Kane, Maureen A; Zhang, Yuji; Ambulos, Nicholas; Weber, David J; Njar, Vincent C O.
Afiliação
  • Thomas E; Department of Pharmacology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Thankan RS; The Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Purushottamachar P; Department of Pharmacology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Huang W; Isoprene Pharmaceuticals Inc., Baltimore, Maryland, USA.
  • Kane MA; Flavocure Biotech, Baltimore, Maryland, USA.
  • Zhang Y; Department of Pharmacology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Ambulos N; The Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Weber DJ; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
  • Njar VCO; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Mol Carcinog ; 61(7): 643-654, 2022 07.
Article em En | MEDLINE | ID: mdl-35512605

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article